z-logo
open-access-imgOpen Access
Development of a Retinal-Based Probe for the Profiling of Retinaldehyde Dehydrogenases in Cancer Cells
Author(s) -
Sebastiaan T. A. Koenders,
Lukas S. Wijaya,
Martje N. Erkelens,
Alexander T. Bakker,
Vera E. van der Noord,
Eva J. van Rooden,
Lindsey Burggraaff,
Pasquale C. Putter,
Else Botter,
Kim Wals,
Hans van den Elst,
Hans den Dulk,
Bogdan I. Florea,
Bob van de Water,
Gerard J. P. van Westen,
Reina E. Mebius,
Herman S. Overkleeft,
Sylvia E. Le Dévédec,
Mario van der Stelt
Publication year - 2019
Publication title -
acs central science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.893
H-Index - 76
eISSN - 2374-7951
pISSN - 2374-7943
DOI - 10.1021/acscentsci.9b01022
Subject(s) - retinaldehyde , aldehyde dehydrogenase , drug discovery , biochemistry , retinal , cancer cell , enzyme , biology , cytotoxicity , computational biology , chemistry , phenotypic screening , cancer , in vitro , genetics , gene , phenotype , rhodopsin
Retinaldehyde dehydrogenases belong to a superfamily of enzymes that regulate cell differentiation and are responsible for detoxification of anticancer drugs. Chemical tools and methods are of great utility to visualize and quantify aldehyde dehydrogenase (ALDH) activity in health and disease. Here, we present the discovery of a first-in-class chemical probe based on retinal, the endogenous substrate of retinal ALDHs. We unveil the utility of this probe in quantitating ALDH isozyme activity in a panel of cancer cells via both fluorescence and chemical proteomic approaches. We demonstrate that our probe is superior to the widely used ALDEFLUOR assay to explain the ability of breast cancer (stem) cells to produce all-trans retinoic acid. Furthermore, our probe revealed the cellular selectivity profile of an advanced ALDH1A1 inhibitor, thereby prompting us to investigate the nature of its cytotoxicity. Our results showcase the application of substrate-based probes in interrogating pathologically relevant enzyme activities. They also highlight the general power of chemical proteomics in driving the discovery of new biological insights and its utility to guide drug discovery efforts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom